Ondansetron is not associated with vascular adverse events, thrombocytopenia or renal failure.
| Autor: | Castle WM, Cunningham K, Kanarek BB |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 1992 Nov; Vol. 3 (9), pp. 773-4. |
| DOI: | 10.1093/oxfordjournals.annonc.a058340 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|